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Abstract 
 
Chronic Myeloid Leukemia (CML) is a well-known myeloproliferative disease characterized by the presence of the 
Philadelphia chromosome and its oncogenic product, BCR-ABL, a constitutively expressed tyrosine kinase that is 
present in the majority of the patients. The treatment of CML was transformed by the introduction of imatinib 
mesylate commercially known as Gleevec; a BCR-ABL tyrosine kinase inhibitor (TKI) which dramatically 
increased the survival rate and quality life of the patients. Despite having high efficacy majority of the patients have 
developed resistance to imatinib. To overcome this problem, new treatment options are required to treat CML 
patients. In this regard, the fragment-based drug discovery is a novel and generic methodology which uses the 
combination of targeted chemotherapeutic drugs with the suitable fragments from the screened library. These ligand-
efficient individual fragments examine the chemical space of the target transporter protein, covering a relatively 
large area due to their small sizes, may provide a way to future medicine to treat CML patients. 
 
Keywords: BCR-ABL, Chronic Myeloid Leukemia, Maybridge Rule of 3 Fragment Library, Philadelphia 
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Introduction 
 
The genetic basis of cancers is commonly seen in 
hematological malignancies due to the presence of 
chromosomal abnormalities. That hematological 
disorder includes the pre-leukemias, 
myeloproliferative disorders and acute leukemias. 
Chronic Myeloid Leukemia (CML) with its well-
defined genetic characterization has given an 
opportunity for both molecular understanding of 
cancer progression and advancement of tools to study 
them. CML is characterized by the increased 
proliferation of hematopoietic stem cells [1-3]. CML 
is genetically distinguished by the presence of the 
reciprocal translocation t (9;22), (q34; q11); the 
Abelson proto-oncogene (abl) on chromosome 9 is 
translocated to the Breakpoint Cluster Region (bcr) 
on chromosome 22, forming a fusion gene in which 
ABL-related tyrosine kinase activity is constitutively 
activated [2, 4, 5]. 
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Diagnosis of CML 
The BCR-ABL fusion protein facilitates the growth 
and development of CML through interaction with 
numerous downstream signaling pathways, resulting 
in changed cellular adhesion, mitogenic signaling 
activation, and apoptotic inhibition leads to the 
alteration of hematopoietic stem cells [6]. The 
defective DNA repair is also associated with BCR-
ABL mediated signaling, resulting in further 
chromosomal aberrations and mutations, which is the 
primary cause of violent nature of advanced phase of 
CML [7]. CML is the highly studied neoplasm [8] 
and it accounts for approximately 15% of all new 
cases of leukemia, affecting about 1-2:100,000 adults 
per year. This disorder affects mostly males (1.4/ 1.3 
%) with a median age of 57-60 years [9-11]. The data 
provided by Indian Cooperative Oncology Network 
(2010) obtained from cancer research institutes 
across India on the basis of clinical examination of 
CML patients have shown the difference in the 
incidence of CML cases i.e., 16.6% at Gujarat Cancer 
and Research Institute (GCRI), Gujarat, to 70% at 
Indira Gandhi Institute of Medical Sciences (IGIMS), 
Regional Cancer Centre (RCC), Patna, Bihar, India 
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[12]. Since, the generation of tyrosine kinase 
inhibitors (TKIs), the survival rate and quality of life 
of CML patients have potentially increased.Despite 
the potentially high efficacy of imatinib, not all but 
approximately 33% of patients have weak response to 
imatinib [13, 14]. Current studies have revealed that 
resistance to imatinib may develop from some 
mechanisms. One of the main reasons for the 
treatment failure is the inadequate response due to the 
point mutation in the ABL kinase domain, leading to 
a structuralchange in the domain and overexpression 
of BCR-ABL [15-17] (Figure 1).The only known risk 
factor that cause damage to the human body in 
younger people is exposure to dose dependent 
radioactive radiation which cause malignancies, 
particularly leukemia[18]. About 40% of CML 
patients are asymptomatic, and diagnosis is 
established during routine blood tests [19]. The 
typical symptoms of the patients are fatigue, weight 
loss, night sweats and abdominal discomfort due to 
splenomegaly [20]. The natural history of CML can 
be progressed through three distinct clinical stages 
termed chronic phase (CP), accelerated phase (AP) 
and blast crisis (BC) [21, 22]. 
 
 
Figure 1: A schematic image of a reciprocal translocation between chromosomes 9 and 22. 
Thetranslocationbetween the two chromosomes is characterized by Philadelphia chromosome in which ABL-
related tyrosine kinase activity is constitutively activated. 
 
 
Figure 2: The clinical procedure for CML therapy is dividedinto chronic, accelerated and blast phase. The 
response of imatinib treatment has been illustrated in the figure. For each response either the continuation of 
therapy with imatinib or next generation, TKIs will be assessed. 
 
The therapeutic response can be evaluated by the 
absence of measurable pH+ related translocations in 
the bone marrow or peripheral blood [23]. The 
cytogenetic examination has a restricted role in the 
detection and follow-up of minimal residual disease 
(MRD),and it has a crucial role in the early 
recognition of inevitablehematological decline [24]. 
The occurrence of any residual leukemic cells 
evading the detection sensitivity of conventional 
diagnostic approaches is termed MRD [25]. 
Numerous molecular techniques are being used to 
detect the BCR-ABL gene. Fluorescent in situ 
hybridization (FISH) is a technique which allows 
quick evaluation of several hundred cells in a time 
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regulated manner. FISHis naturally performed by co-
hybridization of a BCR and ABL probe to denatured 
metaphase chromosomes or interphase nuclei. 
Southern blot analysis has limited sensitivity and 
cannot be used to evaluate minimal residual disease. 
It is widely used in Ph-negative patients to detect Ph-
negative, BCR-ABL-positive CML. Detection and 
quantification BCR-ABL protein may be performed 
by Western blot analysis also. It allows the detection 
of the three BCR-ABL protein isoforms [26]. PCR is 
one of the most sensitive molecular techniques which 
is highly suitable for the evaluation of minimal 
residual disease [27, 28]. The broad implementation 
of strategies for stratified medicine MRD is useful, as 
the therapies lead by quantitative molecular 
measurements are likely to become more usual [3]. 
Bringing all these points together, it is clear that most 
of the patients have undetectable amounts of BCR-
ABL and still continue to undergo a rapid decline 
with the use of imatinib and other TKIs that 
efficiently improved patient survival rate [29].  
 
Treatment options for CML 
Since 1850, many treatment options were recognized 
for CML disease. Treatment choices in CML patients 
are based on the patient’s age and clinical phase of 
the disease [30]. Treatment choices categorized in 
three classes: potentially curative therapy, palliative 
and targeted therapy and combination therapy- 
personalized medicine (Figure 3).Busulfan was used 
as the initial agent to deliver effective hematologic 
control in patients with CML, but its use should be 
discouraged outside the setting of preparative 
regimens for allogeneic SCT [31]. Allogeneic SCT is 
associated with significantly poor survival, worse 
outcome after allogeneic SCT, and highlysevere side 
effects including delayed myelosuppression and 
organ damage [32, 33]. Hydroxyurea has 50–80% 
hematological response and is an outstanding 
debulking agent that permits the fast control of the 
blood count [34]. But, it has rare cytogenetic 
responses and does not appear to change the natural 
history of CML. However, it should not be 
considered as the final therapy for CML. The other 
palliative therapies include 6-mercaptopurine, 6-
thioguanine, cytarabine, melphalan, other 
chemotherapies. 
 
Fig 3:The picturedepicts three different therapeutic classes of CML which have broadly categorized into 
potentially curative therapy, palliative and targeted therapy and new combination therapy and personalized 
medicine
The newly synthesized anticancer drugs are not 
broadly cytotoxic but target proteins, as they are 
crucial for the growth and development of cancer 
cells. Such treatments options are often mentioned as 
targeted therapy and are commonly used along with 
traditional chemotherapeutic agents as follows:  
i. Alkylating agents: The oldest group of 
chemotherapeutics currently in use. Mainly 
derived from mustard gas used in the war field, 
and can alkylate various molecules, including 
proteins, RNA and DNA. 
ii. Anti-metabolites: These resemble nucleosides 
and delay DNA and RNA synthesis by either 
blocking the enzymes required for synthesis. 
iii. Anti-microtubule agents: These are plant-
derived chemicals that block cell division by 
inhibiting microtubule function. 
iv. Topoisomerase inhibitors: Topoisomerase 
inhibitors can affect the activity of two enzymes: 
topoisomerase I and topoisomerase II.  
v. Cytotoxic antibiotics: These antibiotics are a 
diverse group of drugs that have numerous 
mechanisms of action.  
vi. Tyrosine Kinase Inhibitors (TKIs):It is a type 
of pharmaceutical drug which hinders tyrosine 
kinases. Tyrosine kinases are enzymes which are 
responsible for the activation of many proteins 
by signal transduction cascades. The activation 
of proteins takes place by adding a phosphate 
group to it (phosphorylation).  
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Table 1: Classification of chemotherapeutic agents in classes and their respective sub-types with the examples 
used for the treatment of various cancers 
S. No. Class Subtype Example Uses 
1 
Alkylating 
agents 
Nitrogen 
mustards 
Mechlorethamine, 
Cyclophosphamide, Melphalan, 
Chlorambucil, Ifosfamide, Busulfan 
Breast cancer, Lung cancer, 
Lymphocytic leukemia, 
Myelogenous leukemia 
Nitrosoureas 
N-Nitroso-N-methylurea, 
Carmustine, lomustine, 
Streptozotocin 
Hodgkin's disease, 
Myelogenous leukemia 
Tetrazines 
Dacarbazine, Mitozolomide, 
Temozolomide 
Hodgkin's disease, 
Myelogenous leukemia 
Aziridines Thiotepa, Mytomycin, Diaziquone 
Hodgkin's disease, Germ 
cell tumor 
Cisplatin and 
derivatives 
Cisplatin, Carboplatin, Oxaliplatin 
Germ cell tumor, Stomach 
cancer Bladder cancer 
Colorectal cancer 
Nonclassical 
alkylating agents 
Procarbazine, Hexamethylmelamine. Hodgkin's disease 
2 
Anti-
metabolites 
Anti-folates Methotrexate, Pemetrexed 
Breast cancer, Bladder 
cancer, Lymphocytic 
leukemia 
Fluoropyri 
midines 
Fluorouracil, Capecitabine 
Breast cancer, Stomach 
cancer, Colorectal cancer 
Deoxy-
nucleoside 
analogues 
Cytarabine, Gemcitabine, 
Decitabine, Vidaza, Fludarabine, 
Nelarabine, Cladribine, Clofarabine, 
Pentostatin 
Stomach cancer, 
Lymphocytic leukemia 
Thiopurines Thioguanine, Mercaptopurine Lymphocytic leukemia 
3 
Anti-
microtubule 
agents 
Vinca alkaloids 
Natural: Vincristine, Vinblastine 
Synthetic: Vinorelbine, Vindesine, 
Vinflunine 
Hodgkin's disease, Bladder 
cancer Lung cancer 
Taxanes Paclitaxel, Docetaxel Tumor 
Podophyllotoxin Etoposide, Teniposide Germ cell tumor 
4 
Cytotoxic 
antibiotics 
Anthracyclines 
Doxorubicin, Daunorubicin, 
Pirarubicin, Aclarubicin, 
Mitoxantrone 
Breast cancer, Bladder 
cancer, Lymphocytic 
leukemia 
Derivatives Epirubicin, Idarubicin Stomach cancer 
Others 
Actinomycin, Bleomycin, 
Plicamycin, Mitomycin 
Hodgkin's disease, Germ 
cell tumor 
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5 
Topoisomerase 
inhibitors 
Topoisomerase I Camptothecin: Irinotecan, Topotecan 
Metastatic colon or rectal 
cancer 
Topoisomerase 
II 
Poisons: Etoposide, Doxorubicin, 
Mitoxantrone, Teniposide 
Hodgkin's disease, Lung 
cancer 
Catalytic inhibitors: Novobiocin, 
Merbarone, Aclarubicin 
Breast cancer, Tumor 
6 
Tyrosine 
Kinase 
Inhibitors 
PGDFR 
Imatinib, Nilotinib, Dasatinib, 
Bosutinib, Thiadiazole Derivatives 
Colorectal cancer, 
Lymphocytic leukemia, 
Myelogenous leukemia 
 
BCR-ABL Tyrosine Kinase Inhibitors therapy: 
Tyrosine kinases are a different class of enzymes that 
catalyze the transfer of a phosphate group from 
adenosine triphosphate (ATP) to target proteins that 
play a vital role in cell signal cascade that regulate cell 
proliferation, differentiation, anti-apoptotic signal 
transduction andprogrammed cell death [35]. The 
increasing research output has confirmed that imatinib 
exerts major immunomodulatory effects on lymphoid 
cells such as antigen-presenting cells and dendritic 
cells [36].Current research in the field of molecular 
targeted therapieshas transformed cancer treatment. 
The application of TKI therapy could be considered as 
a model for the successful treatment of cancer [37]. In 
the United States, five TKIs have been approved for 
the treatment of CML including imatinib, dasatinib, 
nilotinib, bosutinib and ponatinib [38, 39]. High-
throughput in vitro analysis for TKIs confers 2-
phenylaminopyrimidine formerly known as a signal 
transduction inhibitor 571 (STI 571) as a primary 
compound was optimized for its activity forparticular 
kinases on CML cell lines which is popularly known as 
Imatinib or Imatinib mesylate [40]. Food and Drug 
Administration (FDA; 2001) approved the replacement 
of IFN-α with Imatinib mesylate, a first TKI for CML 
as a standard treatment [2]. Imatinib also showeffect on 
other molecules of the metabolism and receptors for 
cell signaling, for example, BCR-ABL, ABL, ARG, 
PDGFR- α / β, C-kit receptor, and c-FMS receptors etc 
[41]. Clinical evidence indicates that Imatinib mesylate 
acts as an effective and long lasting TKI therapy for 
CML patients and it should be monitored carefully to 
evaluate their response to treatment and the detection 
of early decline. It includes three different kinds of 
responses; hematological response (HR), cytogenetic 
response (CR) and molecular responses (MR) [42-44]. 
A complete hematologic response (CHR) can be 
defined as the normalization of blood counts and 
spleen size. Measure the blood counts every two weeks 
and then testing for every three months till CHR is 
achieved. Cytogenetic response is the most extensively 
used method to observe the response in CML patients. 
The cytogenetic response can be determined by the 
decrease in the number ofPh-positivemetaphasic cells 
by the use of both bone marrow aspiration and 
cytogenetic evaluation systems. The complete absence 
of Ph-positivemetaphasic cells leads to a complete 
cytogenetic response (CCR). A molecular response is 
determined by lowering the amount of BCR-ABL 
chimeric mRNA. The complete absence of detectable 
BCR-ABL chimeric mRNA as measured by reverse 
transcriptase polymerase chain reaction (RT-PCR) is 
referred to as complete molecular response (CMR). All 
tyrosine kinase inhibitors being easily absorbed in the 
gastrointestinal tract which makes them highly suitable 
for the treatment. In addition, not only first TKI 
generation medicines like imatinib but other TKI 
generations also inhibit several different signal 
transduction pathways, which are listed below in the 
table-2.In cancer, mutant kinases frequently act as 
oncogenes that promote tumor cell survival, growth or 
replication by causing aberrations in proliferation, 
apoptotic resistance, angiogenesis and adhesion 
through interference with β-integrin signaling and 
multiple downstream pathways during metastasis [45, 
46]. There is significant evidence that malignant 
transformation of hematopoietic cells by BCR-ABL 
protein depends on its TK activity [3]. The 
inactivationof the BCR-ABL signal transduction 
pathways and prevention of disease development to 
treat CML is promoted by TKI molecule which acts as 
a "smart drug" [47]. TKIs decrease the number of 
malignant cells by competitive inhibition at the ATP-
binding site within BCR-ABL protein,which then leads 
to closed or inactive configuration and inhibition of the 
enzyme activity on substrate proteins [48, 49]. ATP 
prevents tyrosine phosphorylation and downstream 
signaling, resulting in arrested cellular growth and 
apoptosis [50]. The process of competitive inhibition of 
imatinib can be seen in the given figure. 
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Table 2: The TKI generations with their related targets and binding sites, with approval year 
TKI Generations Targets 
Binding Site/ 
Inhibitor type 
Approval 
Year 
First 
Generation 
Imatinib 
Inactive BCR-ABL, PDGFR, 
ARG, KIT, VEGF, DDR1 
ATP Binding site/ 
ATP Competitive 
2001 
Second 
Generation 
Dasatinib 
ARG, TEK, BTK, Active & 
Inactive BCR-ABL, SRC, 
DDR1, EPHA2, PDGFR 
ATP Binding site/ 
ATP Competitive 
2006 
Nilotinib 
ARG, KIT, VEGFR, Inactive 
BCR-ABL, DDR1, NQO2, 
PDGFR, 
ATP Binding site/ 
ATP Competitive 
2007 
Third 
Generation 
Bosutinib 
BCR-ABL, SRC, TEK, 
CAMK2G, C-Kit, PDGFR 
ATP Binding site/ 
ATP Competitive 
2012 
Ponatinib 
All mutated forms of BCR-ABL, 
T351I, FGFR, TIE2, VEGFR 
ATP Binding site/ 
ATP Competitive 
2012 
 
 
Figure 4: Schematic representation of the mechanism of imatinib action which acts as a competitive inhibitor 
at the BCR-ABL protein ATP-binding site. The imatinib blocks the binding of ATP to the BCR-ABL tyrosine 
kinase and inhibit constitutive pathways leading to an inactive configuration and the inhibition of TK activity 
The overall survival of CML patients has dramatically 
increased with the use of TKIs. While during the 
introduction period of imatinib the five-year overall 
survival rate was 24%, which increased steadily to 39% 
(1966-1998) and 56.8% (1999-2006) and the overall 
survival was estimated to 85% [2, 51]. On the other 
hand, lack of adherence to TKIs inevitably results in 
disease progression and treatment resistance [52]. 
Some non-ATP competitive inhibitors such as 
ONO12380 [53], the Aurora kinase inhibitor MK-0457 
(VX-680) [54], and the p-38 inhibitors BIRB-796, 
SGX-70430 [55] are in clinical trial to overcome 
imatinib, nilotinib, or dasatinib resistance in CML 
patients.Although the clinical consequence of these 
new target drugs remains to be explained, it may be 
possible that these drugs play a critical role in the 
efficacy and safety of these drugs.The growing 
evidence indicating that TKIs exerts significant 
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immunomodulatory side-effects include nausea, 
diarrhea, vomiting, muscle pain and fatigue. Almost 
30% of individuals using TKIs show itchy skin rashes 
including myelosuppression [43,56]. Overall, TKIs 
have changed CML from a life-threatening disease (10- 
20% mortality/ year) to a chronic disease that can be 
managed by oral medicines (1-2% mortality/year) [19]. 
The mechanism of resistance to TKI Treatment 
Evidence from clinical trials and in vitro analysis has 
shownthat cells treated with TKIs tend to nullify the 
inhibitory effects of these agents [57]. The rate of 
imatinib resistance within four years was reported up to 
20%, increasing to 70-90% in accelerated phase/ 
blastic phase in CML patients [58-60]. Indeed, 
chromosomal abnormalities like trisomy in 
chromosome number 8 and translocation of oncogenes 
occur, and due to these abnormalities, TKI resistance 
occurs that results to impaired treatment ([46, 61]. 
Based on the clinical trials of the disease, resistance to 
treatment can be sub-divided into primary and 
secondary types. When the frontline therapy has not 
achieved the expected response is called Primary 
resistance [44] whereas secondary resistance develops 
after a targeted response to the frontline therapy was 
completed but subsequently lost [47]. Moreover, the 
primary resistance can be sub-divided into either 
primary hematologic resistance or cytogenetic 
resistance. Additionally, for secondary resistance, the 
following criteria are in practice, i.e., loss of complete 
hematologic remission, loss of complete cytogenetic 
response, loss of major molecular remission, detection 
of kinase mutations with a known failure of sensitivity 
to imatinib, and clonal evolution [62]. Almost about 
33% CML patients have shown that imatinib treatment 
is not much effective due to primary/secondary 
resistances or due to intolerance after six years 
evaluation of the IRIS study [63]. According to many 
pre-clinical and clinical studies, from a mechanistic 
perspective, the emergence of resistance to treatment 
observed in some CML patients can be categorized into 
BCR-ABL-dependent and BCR-ABL independent 
mechanisms. BCR-ABL-dependent mechanisms 
include BCR-ABL mutations and amplification, along 
with impaired signaling pathways. BCR-ABL-
independent mechanisms include drug efflux, mediated 
by ATP-binding cassette (ABC) Transporters, deficient 
base excision repair (BER) for chromosomal 
abnormalities. Overall, understanding the underlying 
causes of resistance is a crucial step towards battling 
CML [64]. BCR-ABL independent mechanisms are 
characterized by deregulations in drug transport [61, 
65]. On the other hand, BCR-ABL-dependent 
mechanisms are characterized by the emergence of 
mutations in several structural sub-units related to 
tyrosine kinase domain, and can be divided into four 
groups: 1. mutations caused by direct binding of TKI, 
2. mutations in the ATP binding site, 3. mutations in 
the activation loop, 4. mutations in the catalytic domain 
[66]. However, not all mutations cause clinical 
resistance to imatinib. The most common mutations 
which together account for about 2/3rd of all mutations 
include T315I, E255D/K/R/V, Y253F/H, G250A/E (P-
or glycine-rich loop), H396P, M351T and 
F359C/L/V/R (C-lobe). T315I mutation is the 
muchcommon type (about 15–20%) and induces 
resistance to nearly all clinically available TKIs, except 
ponatinib. Current studies in CML patients treated with 
imatinib revealed mutations in regions also exterior of 
the kinase domain [67]. Thus, the clinical significance 
of these mutations for almost all CML patients is 
currently unclear. 
Strategy to enhance the TKI efficacy 
With the growing need to modernize the treatment 
process, screening of fragment libraries has become an 
essential tool for this program. The fragment-based 
drug discovery is a novel and generic methodology 
which uses the combination of chemotherapeutic drugs 
with fragments from the Maybridge Rule of 3 
Fragment Library (MBF) to further direct the 
nucleoside analog drugs towards their 
transporters.These ligand-efficient fragments examine 
the chemical space of the target transporter protein, 
covering a relatively large area due to their small sizes. 
This may lead to greater transporter binding, which in 
turn increases the intracellular transportation of drug 
and consequently its drug efficacy. However, the 
success rates are often low, and several hits fail to 
develop into optimization [68, 69]. The understanding 
aboutfragment-based screening to get accurate ‘hits’ is 
rapidly developing by accelerating the drug discovery 
process.  A general approach for hit identification is 
high-throughput screening (HTS) [70]. The Maybridge 
library constructs via choosing thousands of fragments 
from the Maybridge collection of more than 70,000 
compounds are screened to assess their biological 
property against a target.The Maybridge Ro3 Fragment 
Libraries are pharmacophorically-rich compounds. 
Fragment-based screening has a benefit that a few 
hundred to a few thousands of compounds screened 
because of their lower complexity and have a higher 
possibility of matching to a target protein binding site 
[71]. The affinity of the compound is one of the first 
criteria taken in consideration for hit selection and 
optimization during subsequent stages of drug 
discovery. Moreover, affinity is often optimized 
through the introduction of lipophilic groups (cLogP), 
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as these contribute favorably to the hydrophobic effect 
without the need for specific interactions with the 
target. Additionally, molecular size (Mr) should also be 
taken with an affinity to prevent misleading in alone 
[72]. However, ‘Lipinski’s Rule of 5’ [73] is used to 
maximize the probability of surviving development of 
an oral drug based on the number of rotatable bonds 
[74]. Similarly, Congreve and his colleagues (2003) 
proposed a ‘Rule of 3’ (Ro3)[75] for fragment library 
which is based upon a structural study of fragments 
that bind to a number of kinases and protease targets. 
The fragment hits with the following physicochemical 
properties allow an excellent opportunity for the 
development of leads with superior ADME attributes. 
 
Table3: The table illustrates the criteria for fragment- like (Rule of Three) and drug-like (Rule of Five) 
molecules for the development of fragment hits for drug discovery 
Type of Compounds Fragment-like Drug-like 
Rule Rule of Three* [75] Rule of Five [73]  
Thresholds Molecular 
Weight (Mr)  
≤300 ≤500 
Lipophilicity (cLogP) ≤3 ≤5 
H-bond donor ≤3 ≤5 
H-bond acceptor ≤3 ≤5 
*The number of rotatable bonds ≤ 3 and polar surface area ≤ 60 (A0)2 as 
additional criteria. 
 
A group of researchers have documented a Maybridge 
compoundthat targetInositol-3-phosphate synthase 
(INO1) and it has been genetically authenticatedas a 
drug target for Trypanosoma brucei, the causative 
agent of African sleeping sickness. The compound that 
interacts with T. bruceiINO1 was employed to screen 
about670 compounds from May Ro3 fragment library 
and checked for their trypanocide and cytotoxic 
activities [76]. Unfortunately, many of these 
compounds are cytotoxic against mammalian cells, and 
therefore they are unlikely to proceed as a lead 
compound. However, the biological activities of 
associated compounds such as 2-amino-phenol or 269e 
have anti-microbial activity[76]. Therefore, this 
phenomenon is reflected in the general trend towards 
the generation of desired compounds during the hit 
optimization process. It will be more interesting to 
watch the future direction of further developments in 
this field.  
 
Conclusion 
The diagnosis of CML patients has significantly 
enhanced over the last couple of years. Whereas the 
average survival rates was ranging from 4-6 years 
during the different clinical stages of CML. The 
revolutionary development of imatinib has signified 
one of the major breakthroughsin the treatment of 
CML patients. However, imatinib and other TKIs 
efficiently improved patient survival rate, but their 
complete molecular remission (CMR) has been 
achieved by a small number of CML patients only. 
Therefore, the discovery of new compounds that can 
inhibit BCR-ABL is vital to curing the disease. 
Additionally, it has been evident from the result of T. 
brucei that combination of May Ro3 fragment library 
with the drug has the potential to cure the disease. 
Similarly, May Ro3 fragment library with TKIs may 
able to interfere with specific signaling pathways like 
PI-3-kinase and proteasome inhibitors of tumor cells 
and has a significant effect on membrane transporters 
to cure the disease. Therefore, it would likely to be an 
classical model in changing our therapeutic thinking 
and approach, not only in CML but other malignancies 
as well. 
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ARG: abl related gene, BCR-ABL: Break point cluster 
region-Abelson proto-oncogene, BTK: Bruton's 
tyrosine kinase, CAMK2G: Calcium/calmodulin-
dependent protein kinase type II gamma chain, C-Kit: 
tyrosine-protein kinase Kit, DDR1:Discoidin domain 
receptor, EPHA2:Ephrin type-A receptor 2 precursor, 
E255D/K/R/V: Glutamic acid (E) to Aspartic acid (D)/ 
Lysine (K)/ Arginine (R)/ Valine (V) mutation at 
position 255, F359C/L/V/R: Phenylalanine (F) to 
Cysteine (C)/ Leucine (F)/ Valine (V)/ Arginine 
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mutation at position 396, FGFR:Fibroblast growth 
factor receptor, G250A/E: Glycine (G) to Alanine 
(A)/ Glutamic acid (E) mutation at position 250, 
H396P: Histidine (H) to Proline (P)  mutation at 
position 396, M351T: Methionine (M) to Threonine 
(T) mutation at position 396, NQO2: NAD(P)H 
dehydrogenase, quinone 2, PDGFR:Platelet-derived 
growth factor receptor, SRC: Src family kinase, 
STI571: Signal transduction inhibitor 571, TEK: TEK 
receptor tyrosine kinase, TIE2:Angiopoietin receptor, 
T315I: Threonine (T) to Isoleucine (I) mutation at 
position 315, VEGFR:Vascular endothelial growth 
factor receptor, Y253F/H: Tyrosine (Y) to 
Phenylalanine (F)/ Histidine (H)mutation at position 
253. 
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